29 citations
,
July 2009 in “BJU international” This review examines the pharmacological properties and potential clinical benefits of 5α‐reductase inhibition in prostate cancer but reports no new research findings.
April 2017 in “Austin Journal of Cancer and Clinical Research” This article reviews the role and controversies of 5α-reductase inhibitors like finasteride and dutasteride in managing prostate cancer, without presenting new research results.
153 citations
,
March 2017 in “Endocrine” This review examines recent advances in understanding the pathophysiology and molecular mechanisms of androgenetic alopecia, highlighting two major genetic risk loci, but does not report new clinical findings.
100 citations
,
September 1999 in “British Journal of Dermatology” This study suggests that finasteride's effect on promoting hair growth in men with androgenetic alopecia may be due to its inhibition of 5aR2 localized in hair follicles.
9 citations
,
October 2013 in “PLOS ONE” This study suggests that dutasteride may be more beneficial than finasteride for therapeutic or preventive use.